Respiri Limited (ASX: $RSH; OTCQB:RSHUF) has successfully raised $A1 million through an additional placement from sophisticated and professional investors. The placement involves issuing 33,333,333 new fully paid ordinary shares at an issue price of $0.03 per share, representing a 3.45% premium to the company's last closing price. This funding, in addition to prior placements, brings the total raised to A$9.1M, supporting the company's strategic initiatives and general working capital purposes.
Respiri is pleased with the strong market support and strategic opportunities generated by its broadening stakeholder base and core Remote Patient Monitoring (RPM) offering rollout. The funds raised will be utilized for patient profiling, segmentation, targeting, and onboarding of contracted clients, as well as accelerating the 'Clinic in Cloud' programs to expand RPM and service business in the US. This positions the company to reach a monthly breakeven performance in late CY 2024, reflecting confidence in our strategy and execution capability.
Respiri Limited (ASX: $RSH) has successfully secured $1 million through an additional placement, demonstrating strong market support and confidence in the company's strategic direction. The funds will be used to advance patient profiling, segmentation, targeting, and onboarding, as well as accelerate the 'Clinic in Cloud' programs to expand the company's RPM and service business in the US. This additional funding is expected to support Respiri's goal of reaching a monthly breakeven performance in late CY 2024, reflecting the company's ambitions to improve respiratory healthcare management and remote patient monitoring services.